HAE - Haemonetics Corporation
| Previous Close | 127.25 |
| Open | 127.57 |
| Bid | 123.42 x 900 |
| Ask | 123.47 x 900 |
| Day's Range | 123.27 - 128.39 |
| 52 Week Range | 80.24 - 140.36 |
| Volume | 168,125 |
| Avg. Volume | 346,633 |
| Market Cap | 6.263B |
| Beta (3Y Monthly) | 0.69 |
| PE Ratio (TTM) | 132.66 |
| EPS (TTM) | 0.93 |
| Earnings Date | Nov 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 146.17 |
- Investor's Business Daily Video
Investing Strategies: Can Haemonetics Stock Find Support At 50-Day?
Blood management firm Haemonetics is pulling back to a support level, which could potentially provide investors with a new buying opportunity.
- Zacks
Here's Why You Should Hold on to Chemed (CHE) Stock Right Now
Investors continue to be optimistic about Chemed's (CHE) performance.
- Insider Monkey
Here is What Hedge Funds Think About Haemonetics Corporation (HAE)
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of June 28. In this […]
- Simply Wall St.
How Much Are Haemonetics Corporation (NYSE:HAE) Insiders Taking Off The Table?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- Zacks
Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.
- Zacks
Here's Why You Should Hold on to Quest Diagnostics Stock Now
Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.
- Zacks
Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System
The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.
- Zacks
Haemonetics Grows on Strong Plasma, Hemostasis Management
Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.
- Zacks
Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.
- Zacks
Here's Why You Should Hold GNC Holdings (GNC) Stock for Now
Investor confidence continues to be high in GNC Holdings (GNC), thanks to solid prospects.
- Zacks
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
- Zacks
Medtronic's MiniMed 670G Shows Favorable Outcome in Europe
Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.
- Zacks
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
- Zacks
Align Technology Inks Distribution Deal With Zimmer Biomet
This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.
- Simply Wall St.
What Does Haemonetics Corporation’s (NYSE:HAE) 12% ROCE Say About The Business?
Today we are going to look at Haemonetics Corporation (NYSE:HAE) to see whether it might be an attractive investment...
- Zacks
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
- Zacks
Here's Why You Should Retain Globus Medical (GMED) Stock Now
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.
- PR Newswire
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2020 Results: November 1, 2019
BRAINTREE, Mass. , Sept. 17, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2020 financial results at 6:00 am EDT on Friday, ...
- Zacks
Intersect ENT Rides on Innovation Amid Pricing Concerns
The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.
- Zacks
Medtronic Collaborates With Novo Nordisk for Diabetes Care
This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.
- Thomson Reuters StreetEvents
Edited Transcript of HAE earnings conference call or presentation 6-Aug-19 12:00pm GMT
Q1 2020 Haemonetics Corp Earnings Call
- PR Newswire
Haemonetics Appoints Stewart W. Strong As President, Global Hospital
BRAINTREE, Mass. , Sept. 12, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient ...
- Zacks
Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well
The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.
- Zacks
Haemonetics (HAE) Down 0.4% Since Last Earnings Report: Can It Rebound?
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Here's Why You Should Invest in Haemonetics (HAE) Right Now
Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.
